Skip to content

Wall Street Sun Tzu

Real trading signals pulled from social media

  • About
  • Privacy Policy
  • Contact
  • Disclaimer

oscar

Oscar Health insiders buy shares. Directors Plouffe and Boyd added July 10. $3B cash. $0.92 EPS. Mixed analyst ratings.

July 16, 2025 1:47 pm

Oscar Health is drawing fresh attention after two of its directors, David Plouffe and Jeffery H. Boyd, added shares on July 10. The insider buying wasn’t symbolic. It was coordinated. Both men acquired 14,134 shares each, according to Nasdaq filings. … Read more

Leave a comment

Oscar prints $1.1 billion in free cash flow. Stock trades at just 4x cash flow. Routing engine deflates claims at scale.

July 15, 2025 2:09 pmJuly 11, 2025 10:06 pm

Oscar Health is sitting on a pile of cash and trading like it’s invisible. Over the last twelve months, the company generated $1.19 billion in free cash flow. That’s not projected. That’s booked. The stock is trading at $14.38, which … Read more

Leave a comment

Oscar Health hits $10B. Hims & Hers on track for $2.4B in 2025. Both firms now building full-stack health platforms.

July 15, 2025 2:48 pmJuly 6, 2025 1:21 pm

Revenue growth like this doesn’t come from noise. It happens when a company locks in product fit and turns it into system-wide expansion. Two firms are now flashing numbers that match the kind of vertical control tech investors chase. Oscar … Read more

Leave a comment

Oscar crashes 22% in two days but call buyers and hedge funds refuse to flinch

July 15, 2025 2:49 pmJuly 3, 2025 11:46 pm

Oscar Health just got body slammed. The stock plummeted over 22% from its late June high of $21.53 and sank to $16.70 in a flash. But here’s what caught traders’ eyes. Nearly 77 million shares traded hands in a single … Read more

Leave a comment

Oscar Health targets $2.25 EPS by 2027. 20% revenue CAGR. AI stack live. ICHRA expansion underway.

July 15, 2025 2:49 pmJuly 3, 2025 2:25 am

Oscar Health is not playing by the old insurance playbook. The company turned profitable in 2024 and is now projecting at least 20% compound annual revenue growth through 2027. That’s not a stretch goal. That’s internal guidance. EPS is expected … Read more

Leave a comment

Oscar Health is breaking out. EPS just jumped 164% year over year. Quarterly revenue passed $3 billion. Cash on hand totals $4.9 billion. Insiders are buying millions.

July 15, 2025 2:49 pmJuly 2, 2025 1:09 am

Oscar Health is being priced like an afterthought and performing like a breakout. The Q1 numbers confirm it, the insider trades back it, and the float is moving. This isn’t crowd hype. It’s internal conviction and raw financials that are … Read more

Leave a comment

Oscar Health is up 50% in 6 months. But with 2M+ members, 42% revenue growth, and a tech stack that processes 98% of claims automatically, this might just be the warm-up.

July 15, 2025 2:50 pmJune 29, 2025 1:01 pm

Oscar Health is not your grandfather’s insurance company. It is a digital-native operator that just posted $3.05 billion in Q1 revenue, up 42% year over year. Net income hit $275 million. That is not a typo. That is a profitable … Read more

Leave a comment

Trending

Archives

  • July 2025
  • June 2025

Categories

  • Market News & Marco Pulse
  • Options Trading
  • Personal Finance
  • Smart Money
  • Stocks & ETFs

Recent Posts

  • Carvana stock hits $343 after 152% rally. Analysts chase $440 targets. Short interest climbs. Valuation stretched. Time to fade the hype?
  • Oscar Health insiders buy shares. Directors Plouffe and Boyd added July 10. $3B cash. $0.92 EPS. Mixed analyst ratings.
  • Palantir now valued higher than Bank of America despite earning 58 times less
  • UnitedHealth $UNH now trades at the largest P/E gap to the S&P 500 since its IPO. 12.2x earnings. 3.03% yield. 42% upside target.
  • Palantir now trades at 84x EV/Revenue. Higher than $NET during the 2021 mania. Great company, but the price is running hot. Will history rhyme?
Disclaimer: Nothing on this site is financial advice or a recommendation. All content is for educational purposes only. Please do your own research before making any financial decisions.
© 2025 Wall Street Sun Tzu • Built with GeneratePress